0QNS Stock Chart & Stats
CHF18.75
-CHF0.90(-4.58%)
―
--
Day’s Range― - ―
52-Week RangeCHF11.55 - CHF25.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)22.00
Market Cap
CHF101.72M
Enterprise ValueCHF111.64
Total Cash (Recent Filing)CHF3.60M
Total Debt (Recent Filing)CHF0.00
Price to Earnings (P/E)―
Beta-0.46
Next Earnings
Apr 12, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding5,313,449
10 Day Avg. Volume24
30 Day Avg. Volume22
Financial Highlights & Ratios
PEG Ratio0.53
Price to Book (P/B)1.30
Price to Sales (P/S)5.54
P/FCF Ratio-23.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)16.79
Revenue Forecast (FY)CHF99.00M
Bulls Say, Bears Say
Bulls Say
Revenue And Margin RecoveryThe sharp revenue rebound and higher gross margin indicate improving commercial traction and operating economics. If maintained, this combination can strengthen the company’s revenue base, improve contribution from future sales, and provide a clearer path toward eventual profitability.
Debt-Free Balance SheetZero reported debt and a substantial equity base give Curatis financial flexibility while it develops its pharmaceutical and healthcare operations. The absence of debt-related obligations reduces balance-sheet pressure and preserves capacity to support operations or pursue growth initiatives.
Material Loss ReductionA substantial reduction in net losses shows that the business is moving in a better direction financially, even though it has not reached profitability. Continued progress could reduce the resources required to sustain operations and improve the durability of the company’s recovery.
Bears Say
Persistent Negative Cash FlowNegative operating and free cash flow mean the business is not yet self-funding, despite improved revenue and narrower losses. Continued cash burn could require further funding and may constrain investment in growth, making cash conversion a central risk over the coming quarters.
Profitability Not Yet EstablishedCuratis has not yet demonstrated sustainable profitability across its core earnings measures. Ongoing negative EBIT, EBITDA, and net income limit internal capital generation and leave the company dependent on further operational improvement before its business model can support itself consistently.
Negative Returns On EquityA negative return on equity shows that the company’s sizeable capital base is currently producing losses rather than shareholder returns. Unless operating performance improves, capital may remain underutilized and the balance-sheet strength will not translate into durable earnings power.
Curatis Holding AG News
0QNS FAQ
What was Curatis Holding AG’s price range in the past 12 months?
Curatis Holding AG lowest share price was CHF11.55 and its highest was CHF25.00 in the past 12 months.
What is Curatis Holding AG’s market cap?
Curatis Holding AG’s market cap is CHF101.72M.
When is Curatis Holding AG’s upcoming earnings report date?
Curatis Holding AG’s upcoming earnings report date is Apr 12, 2027 which is in 199 days.
How were Curatis Holding AG’s earnings last quarter?
Curatis Holding AG released its earnings results on Sep 21, 2026. The company reported -CHF0.078 earnings per share for the quarter.
Is Curatis Holding AG overvalued?
According to Wall Street analysts Curatis Holding AG’s price is currently Undervalued.
Does Curatis Holding AG pay dividends?
Curatis Holding AG does not currently pay dividends.
What is Curatis Holding AG’s EPS estimate?
Curatis Holding AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Curatis Holding AG have?
Curatis Holding AG has 5,313,449 shares outstanding.
What happened to Curatis Holding AG’s price movement after its last earnings report?
Curatis Holding AG reported an EPS of -CHF0.078 in its last earnings report. Following the earnings report the stock price went up 2.743%.
Which hedge fund is a major shareholder of Curatis Holding AG?
Currently, no hedge funds are holding shares in GB:0QNS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Curatis Holding AG
Curatis Holding AG specializes in the entire lifecycle of pharmaceutical products, including the procurement, advancement, and market release of medications specifically designed for the diagnosis, prevention, and management of rare and specialized medical conditions. The company's extensive product offerings span a broad array of therapeutic areas. These encompass treatments for antiplatelet conditions, metastatic hormone receptor-positive breast cancer, anti-arrhythmic disorders, nasal oil applications, Wilson's disease, antidotes for cyanide poisoning and digoxin toxicity, antihypotensive agents, therapies for bladder pain syndrome/interstitial cystitis, antibiotics, diagnostic tools for ophthalmology, antivirals, ophthalmic/antibiotic combinations, gentamycin collagen sponges, solutions for benign prostatic hyperplasia, immunomodulators, treatments for epilepsy and essential tremor, thyreostatics, therapies for hereditary tyrosinemia type 1, gastroenterological products, additional immunomodulators and thyreostatics, tranquilizers, Helicobacter pylori tests, phosphate binders, specialized nutritional support for dialysis patients, dermatological corticosteroids, antidotes for lead and mercury poisoning, corticostimulants, anti-fog agents, treatments for chorea associated with Huntington's disease, and antiepileptics. In addition to its commercialized portfolio, Curatis is actively engaged in developing new pharmaceutical compounds. Its pipeline includes C-PTBE-01, currently in Phase IIb clinical trials for treating peritumoral brain edema in pediatric patients; C-AM-01, undergoing Phase IIa trials for preventing severe migraine with aura; and C-MOH-01, also in Phase IIa for the treatment and prevention of medication overuse headache. Furthermore, KIN001 is in Phase I clinical trials, targeting rare inflammatory and fibrotic diseases. The company maintains its headquarters in Liestal, Switzerland.